Denosumab and Risk of Type 2 Diabetes Risk Among Patients With Osteoporosis: A Retrospective Cohort Study
Authors' conclusion
Among patients with osteoporosis, IV bisphosphonates were associated with a lower risk of incident T2D compared with denosumab.
Study context
- Population
- Patients with osteoporosis initiating intravenous (IV) bisphosphonates or denosumab, TriNetX database 2016–2024matched cohort
- Participants
- 20,735 vs 20,735
- Exposure
- IV bisphosphonates vs denosumab
- IV bisphosphonatesn = 20,735
- Denosumabn = 20,735reference
- Outcome
- Incident T2D (ICD-10 code E11 or initiation of antidiabetic medications)
Methodological detailspropensity-score matched (1:1), TriNetX database
- Propensity-score matched (1:1)
- TriNetX database
Main finding
As reported in the abstract
Incident T2D · 1, 3, 5 and 7 years
IV bisphosphonates vs DenosumabHazard ratio (95% CI)P value
1 year
0.745(0.649–0.856)
P < 0.0013 years
0.806(0.731–0.890)
P < 0.0015 years
0.818(0.747–0.895)
P < 0.0017 years
0.821(0.753–0.896)
P < 0.001Observational data: associations, not effects.
Further findings
Incident T2D by subgroup
- Females, HR
- 0.739
- Aged ≥65 years, HR
- 0.688
- Whites, HR
- 0.799
- Black or African Americans, HR
- 0.608
- Subgroup analyses demonstrated consistent risk reduction
Original publication
Denosumab and Risk of Type 2 Diabetes Risk Among Patients With Osteoporosis: A Retrospective Cohort Study. Endocr Pract. Published 5 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →